By FSD Pharma on Thursday, 18 March 2021
Category: Vertically Integrated

FSD Pharma CEO addresses upcoming shareholder meeting, forms license agreement with Innovet Italia

FSD Pharma Inc (NASDAQ:HUGE) (CSE:HUGE) (FRA:0K9A) CEO Raza Bokhari talks to Proactive about the group's upcoming shareholder meeting on May 14, intended to address shareholder concerns.

What's more, Bokhari says the company has formed a license agreement with Innovet Italia SRL to develop FDA-approved veterinary drugs for the treatment of gastrointestinal diseases in dogs and cats.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of FSD Pharma named herein, including the promotion by the Company of FSD Pharma in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Related Posts